NEKTAR THERAPEUTICS (NKTR) is a publicly traded company in the Unknown sector. Across all available filings, 33 corporate insiders have executed 928 transactions totaling $258.0M, demonstrating a bearish sentiment with -$254.8M in net insider flow. The most recent transaction on Feb 18, 2026 involved a sale of 423 shares valued at $30.9K.
No significant insider buying has been recorded for NKTR in the recent period.
No significant insider selling has been recorded for NKTR in the recent period.
Based on recent SEC filings, insider sentiment for NKTR is bearish with an Insider Alignment Score of 1/100 and a net flow of -$254.8M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at NEKTAR THERAPEUTICS (NKTR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 33 insiders are actively trading NKTR stock, having executed 928 transactions in the past 90 days. The most active insider is Howard W. Robin (Executive), who has made 170 transactions totaling $137.2M.
Get notified when executives and directors at NKTR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | W. Robin Howard | Executive | Sale | 423 | $73.00 | $30.9K | |
| Feb 18, 2026 | Zalevsky Jonathan | Chief R&D Officer | Sale | 180 | $73.00 | $13.1K | |
| Jan 20, 2026 | Zalevsky Jonathan | Chief R&D Officer | Sale | 3,867 | $35.67 | $137.9K | |
| Dec 22, 2025 | W. Robin Howard | Executive | Award | 21,667 | $N/A | $0 | |
| Dec 22, 2025 | Zalevsky Jonathan | Executive | Award | 6,250 | $N/A | $0 | |
| Nov 25, 2025 | W. Robin Howard | Executive | Sale | 2,207 | $54.28 | $119.8K | |
| Nov 25, 2025 | Andrew Wilson Mark | Executive | Sale | 630 | $54.28 | $34.2K | |
| Nov 25, 2025 | Zalevsky Jonathan | Executive | Sale | 1,157 | $54.28 | $62.8K | |
| Nov 21, 2025 | W. Robin Howard | Executive | Award | 7,110 | $N/A | $0 | |
| Nov 21, 2025 | Andrew Wilson Mark | Executive | Award | 1,903 | $N/A | $0 | |
| Nov 21, 2025 | Zalevsky Jonathan | Executive | Award | 2,666 | $N/A | $0 | |
| Sep 9, 2025 | W. Robin Howard | Executive | Sale | 1,210 | $48.18 | $58.3K | |
| Sep 9, 2025 | W. Robin Howard | Executive | Sale | 2,156 | $47.49 | $102.4K | |
| Sep 9, 2025 | W. Robin Howard | Executive | Sale | 1,200 | $46.41 | $55.7K | |
| Sep 9, 2025 | W. Robin Howard | Executive | Sale | 2,100 | $45.16 | $94.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 465 | $256.4M | 74.0% |
Exercise(M) | 270 | $79.9M | 23.1% |
Disposition(D) | 14 | $7.9M | 2.3% |
Purchase(P) | 14 | $1.6M | 0.5% |
Award(A) | 156 | $439.8K | 0.1% |
Gift(G) | 9 | $0 | 0.0% |
Insider selling pressure at NEKTAR THERAPEUTICS has increased, with 33 insiders executing 928 transactions across all time. Total sales of $256.4M significantly outpace purchases of $1.6M, resulting in a net outflow of $254.8M. This selling activity appears largely discretionary, which may warrant closer attention from investors.